PFE logo Pfizer +
Pfizer
+
Revenue breakdown by Products & Services
Revenue breakdown by Geography

Pfizer's Revenue by Segment

In fiscal year 2025, Pfizer's revenue by segment (products & services) are as follows:

  • Biopharma Segment: $61.20 B
  • Segment Reporting, Reconciling Item, Corporate Nonsegment: $1.38 B

Learn more about Pfizer’s Revenue by Geography

Check out competitors to Pfizer in a side-by-side comparison.

Explore additional financial metrics for Pfizer.

Continue reading...

The above chart shows Pfizer's revenue percentage share by segment (products and services).

In fiscal year 2023, Pfizer's revenue by segment is as follows:

  • Biopharma Segment generated $57.19 B in revenue, representing 97.76% of its total revenue.
  • Business Innovation Segment generated $1.31 B in revenue, representing 2.24% of its total revenue.

The biggest segment for Pfizer is the Biopharma Segment, which represents 97.76% of its total revenue.
The smallest segment for Pfizer is the Business Innovation Segment, which represents 2.24% of its total revenue.

The above chart shows Pfizer's revenue percentage share by segment (products and services).

In fiscal year 2024, Pfizer's revenue by segment is as follows:

  • Biopharma Segment generated $62.40 B in revenue, representing 100% of its total revenue.

The biggest segment for Pfizer is the Biopharma Segment, which represents 100% of its total revenue.
The smallest segment for Pfizer is the Biopharma Segment, which represents 100% of its total revenue.

The above chart shows Pfizer's revenue percentage share by segment (products and services).

In fiscal year 2025, Pfizer's revenue by segment is as follows:

  • Biopharma Segment generated $61.20 B in revenue, representing 97.79% of its total revenue.
  • Segment Reporting, Reconciling Item, Corporate Nonsegment generated $1.38 B in revenue, representing 2.21% of its total revenue.

The biggest segment for Pfizer is the Biopharma Segment, which represents 97.79% of its total revenue.
The smallest segment for Pfizer is the Segment Reporting, Reconciling Item, Corporate Nonsegment, which represents 2.21% of its total revenue.
Continue reading...

Summary Table

Products & Services (Percent Share) 2023 2024 2025
Biopharma Segment 97.76% 100% 97.79%
Business Innovation Segment 2.24% - -
Segment Reporting, Reconciling Item, Corporate Nonsegment - - 2.21%
Total Revenue 100% 100% 100%

The above chart shows the revenue trend of different segments of Pfizer.

In fiscal year 2025, the Biopharma Segment generated the most revenue ($61.20 B), and the Segment Reporting, Reconciling Item, Corporate Nonsegment generated the least revenue ($1.38 B).

The above chart shows growth drivers and a year-over-year comparison of different segments' revenue.

  • Biopharma Segment revenue decreased -1.92% ($1.20 B) from $62.40 B (in 2024) to $61.20 B (in 2025).
  • Segment Reporting, Reconciling Item, Corporate Nonsegment revenue increased 100% ($1.38 B) from $0.00 (in 2024) to $1.38 B (in 2025).
    • Continue reading...

    Summary Table

    Products & Services 2023
    Value Change
    		2024
    Value Change
    		2025
    Value Change
    Biopharma Segment $57.19 B - $62.40 B
    9.12%
    		$61.20 B
    1.92%
    Business Innovation Segment $1.31 B - - - - -
    Segment Reporting, Reconciling Item, Corporate Nonsegment - - - - $1.38 B -
    Total Revenue $59.55 B - $63.63 B
    6.84%
    		$62.58 B
    1.65%

    Frequently Asked Questions

    What was Pfizer's largest product segment last year?

    In fiscal year 2025, Biopharma Segment revenue reached $61.20 Billion, representing 97.79% of Pfizer's total revenue and making it the largest segment for the company.

    Related company

    Submit feedback to Bullfincher